IL-17 and limits of success.
IL-17 and limits of success.
复制标题
DOI：
10.1016/j.cellimm.2018.09.001
复制
发表时间：
2019-05
影响因子：
4.3
通讯作者：
Hamad ARA
中科院分区：
文献类型：
--
作者：
Omidian Z;Ahmed R;Giwa A;Donner T;Hamad ARA
Interleukin-17 (IL-17) is a potent proinflammatory cytokine that protects host against fungal and extracellular bacterial infections. On the other hand, excessive or dysregulated production of IL-17 underlines susceptibility to autoimmune disease. Consequently, blocking IL-17 has become an effective strategy for modulating several autoimmune diseases, including multiple sclerosis (MS), psoriasis, and rheumatoid arthritis (RA). Notably, however, IL-17 blockade remains ineffective or even pathogenic against important autoimmune diseases such as inflammatory bowel disease (IBD). Furthermore, efficacy of IL-17 blockade against other autoimmune diseases, including type 1 diabetes (T1D) is currently unknown and waiting results of ongoing clinical trials. Coming years will determine whether efficacy of IL-17 blockade is limited to certain autoimmune diseases or it can be extending to other autoimmune diseases. These efforts include new clinical trials aimed at testing second-generation agents with the goal of increasing efficiency, spectrum and ameliorating side effects of IL-17 blockade. Here we briefly review the roles of IL-17 in pathogenesis of selected autoimmune diseases and provide updates on ongoing and recently completed trials of IL-17 based immunotherapies.
登录
查看更多内容
影响因子：
64.8
作者：
Bettelli, E;Carrier, YJ;Kuchroo, VK
通讯作者：
Kuchroo, VK
影响因子：
2.8
作者：
Baharlou, Rasoul;Ahmadi-Vasmehjani, Abbas;Khoubyari, Mahshid
通讯作者：
Khoubyari, Mahshid
影响因子：
4.1
作者：
Annunziato, Francesco;Cosmi, Lorenzo;Romagnani, Sergio
通讯作者：
Romagnani, Sergio
影响因子：
3.5
作者：
Bossowski, Artur;Moniuszko, Marcin;Kahaly, George J.
通讯作者：
Kahaly, George J.
影响因子：
3.7
作者：
Domingues HS;Mues M;Lassmann H;Wekerle H;Krishnamoorthy G
通讯作者：
Krishnamoorthy G